Celularity Inc. (CELU)Healthcare | Biotechnology | Florham Park, United States | NasdaqCM
1.22 USD
-0.02
(-1.613%) ⇩
(April 21, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | April 19, 2026, 1:11 a.m. EDT
A deep-value biotech shell facing an extended regulatory delisting saga due to late annual reports. While it received a $15M upfront payment for its skin substitute portfolio, the stock is punishing itself with declining revenue (-43% YoY) and severe operating losses, driving it to a cash-trapped stock priced at less than 39 cents on the dollar. The technicals are broken out with heavy selling pressure at moving averages, and the 'hot take' is that despite positive news flow regarding the license deal, the fundamental rot in the core business and governance issues make it a high-risk, speculative trade with little to no safety margin for traditional investors. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.041252 |
| AutoARIMA | 0.041252 |
| MSTL | 0.043955 |
| AutoTheta | 0.137569 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.089 |
| Excess Kurtosis | 0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.687 |
| Market Cap | 35,182,104 |
| Forward P/E | -2.14 |
| Beta | 0.71 |
| Profit Margins | -198.75% |
| Previous Name | GX Acquisition Corp. |
| Website | https://www.celularity.com |
As of April 19, 2026, 1:11 a.m. EDT: Options flow shows a distinct contrast between calls and puts. Call activity is overwhelmingly ATM-to-OTM, but concentrated in the 09/28 and multi-year strikes, with very low liquidity in near-term OTM strikes (April). Put activity is similarly sparse but heavily concentrated in ATM (2.5 strike) and slightly OTM positions, while call volume is negligible across all near-term expirations. The lack of near-term OTM call volume suggests limited expectations of a sharp rally within weeks, while the presence of ATM put OI at the 2.5 strike (above current price of ~1.23) combined with the price action suggests a hedging stance for a potential drift lower or sideways support at the 2.00 level, rather than pure bearish sentiment. However, the near-term call IV is elevated (20.88) compared to longer-term calls (1.38), indicating hidden fear or anticipation of a specific event in the next month despite the lack of volume.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24223602 |
| Address1 | 170 Park Avenue |
| All Time High | 134.0 |
| All Time Low | 1.001 |
| Ask | 1.34 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 20,100 |
| Average Daily Volume3 Month | 154,759 |
| Average Volume | 154,759 |
| Average Volume10Days | 20,100 |
| Beta | 0.705 |
| Bid | 1.17 |
| Bid Size | 10 |
| Board Risk | 9 |
| Book Value | -0.712 |
| City | Florham Park |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.22 |
| Current Ratio | 0.162 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.3 |
| Day Low | 1.22 |
| Display Name | Celularity |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,547,200 |
| Ebitda | -41,355,000 |
| Ebitda Margins | -1.01915 |
| Enterprise To Ebitda | -2.447 |
| Enterprise To Revenue | 2.494 |
| Enterprise Value | 101,203,232 |
| Eps Forward | -0.57 |
| Eps Trailing Twelve Months | -3.33 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2733 |
| Fifty Day Average Change | -0.053300023 |
| Fifty Day Average Change Percent | -0.04185975 |
| Fifty Two Week Change Percent | -24.223602 |
| Fifty Two Week High | 4.35 |
| Fifty Two Week High Change | -3.1299999 |
| Fifty Two Week High Change Percent | -0.71954024 |
| Fifty Two Week Low | 1.01 |
| Fifty Two Week Low Change | 0.21000004 |
| Fifty Two Week Low Change Percent | 0.20792083 |
| Fifty Two Week Range | 1.01 - 4.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,565,271,000,000 |
| Float Shares | 18,416,038 |
| Forward Eps | -0.57 |
| Forward P E | -2.140351 |
| Free Cashflow | 12,793,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 123 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.50606 |
| Gross Profits | 20,535,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.36546 |
| Held Percent Institutions | 0.12965 |
| Implied Shares Outstanding | 28,837,787 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,735,603,200 |
| Last Split Date | 1,709,164,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey. |
| Long Name | Celularity Inc. |
| Market | us_market |
| Market Cap | 35,182,104 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_408304689 |
| Most Recent Quarter | 1,759,190,400 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -80,647,000 |
| Next Fiscal Year End | 1,767,139,200 |
| Non Diluted Market Cap | 35,470,478 |
| Open | 1.27 |
| Operating Cashflow | -6,557,000 |
| Operating Margins | -2.43168 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 908 768 2170 |
| Pre Market Change | -0.00999999 |
| Pre Market Change Percent | -0.81300735 |
| Pre Market Price | 1.22 |
| Pre Market Time | 1,776,844,814 |
| Prev Name | GX Acquisition Corp. |
| Previous Close | 1.24 |
| Price Hint | 4 |
| Price To Book | -1.7134832 |
| Price To Sales Trailing12 Months | 0.8670241 |
| Profit Margins | -1.98746 |
| Quick Ratio | 0.104 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.01999998 |
| Regular Market Change Percent | -1.6129017 |
| Regular Market Day High | 1.3 |
| Regular Market Day Low | 1.22 |
| Regular Market Day Range | 1.22 - 1.3 |
| Regular Market Open | 1.27 |
| Regular Market Previous Close | 1.24 |
| Regular Market Price | 1.22 |
| Regular Market Time | 1,776,801,600 |
| Regular Market Volume | 38,682 |
| Return On Assets | -0.25029 |
| Revenue Growth | -0.432 |
| Revenue Per Share | 1.687 |
| Sand P52 Week Change | 0.3140242 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 28,837,787 |
| Shares Percent Shares Out | 0.010199999 |
| Shares Short | 294,642 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 309,422 |
| Short Name | Celularity Inc. |
| Short Percent Of Float | 0.045 |
| Short Ratio | 0.78 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CELU |
| Total Cash | 120,000 |
| Total Cash Per Share | 0.004 |
| Total Debt | 66,762,000 |
| Total Revenue | 40,578,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.91608 |
| Two Hundred Day Average Change | -0.69607997 |
| Two Hundred Day Average Change Percent | -0.36328337 |
| Type Disp | Equity |
| Volume | 38,682 |
| Website | https://www.celularity.com |
| Zip | 7,932 |